imatinib discontinuation

OTHER2 trials

Sponsors

University of Campinas, Brazil, University of Sao Paulo General Hospital

Conditions

Leukemia, Chronic MyeloidLeukemia, Myeloid, Chronic-Phase

Phase 2

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response

CompletedNCT02852486

University of Campinas, BrazilLeukemia, Chronic Myeloid

Start: 2016-06-22End: 2024-02-07Updated: 2025-03-30

Unknown Phase

Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log

University of Sao Paulo General HospitalLeukemia, Myeloid, Chronic-Phase

Start: 2016-12-15End: 2020-01-31Updated: 2018-03-23

Related Papers

Tyrosine Kinase Inhibitor Withdrawal Syndrome in Chronic Myeloid Leukemia Patients Participants of Two Discontinuation Clinical Trials

Blood2023-11-023 citations

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response

Blood2022-11-153 citations

Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials

Blood2022-11-15

ESTUDO DE DESCONTINUAÇÃO DE FASE I/II DE IMATINIBE APÓS PIOGLITAZONA (EDI-PIO) EM PACIENTES COM LEUCEMIA MIELOIDE CRÔNICA EM RESPOSTA MOLECULAR PROFUNDA SUSTENTADA – ANÁLISE DE 5 ANOS DE SEGUIMENTO

Hematology Transfusion and Cell Therapy2022-10-01

TREATMENT-FREE RESPONSE USING BRAZILIAN IMATINIB COPIES AS FIRST LINE -RESULTS FROM TWO PROSPECTIVE CLINICAL TRIALS

Hematology Transfusion and Cell Therapy2022-10-01

Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.

2021-07-243 citations

MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.

2021-01-214 citations

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Blood2019-11-136 citations

Pioglitazone Did Not Affect PPAR-Γ, STAT5, HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Blood2019-11-136 citations

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Blood2019-11-134 citations

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Blood2017-12-071 citations